Spinocerebellar Ataxia (SCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Spinocerebellar ataxia (SCA) represents a diverse and heterogeneous collection of autosomal dominant degenerative disorders. These conditions are characterized by the progressive degeneration of the cerebellum and its associated nerve connections, along with typical involvement of structures like the basal ganglia, brainstem nuclei, pyramidal tracts, posterior column, anterior horn, peripheral nerves, and other parts of the nervous system. Clinically, SCAs manifest as cerebellar gait and limb ataxia, accompanied by various associated symptoms such as dysmetria, dysdiadochokinesia, intention tremor, dysarthria, and nystagmus. Additionally, extracerebellar signs may emerge, including ophthalmoplegia, pyramidal signs, movement disorders (like parkinsonism, dystonia, myoclonia, and chorea), dementia, epilepsy, visual impairments (such as pigmentary retinopathy), lower motor neuron disease, and peripheral neuropathy. Several types of spinocerebellar ataxia exhibit a phenomenon known as anticipation, marked by a tendency for gradual expansion of CAG repeats across successive generations. Notably, CAG repeat expansion is observed in SCA1, 2, 3, 6, 7, 8, 12, and 17. Similarly, SCA 10 is attributed to the expansion of ATTCT (a pentanucleotide repeat), while SCA 31, 36, and 37 involve amplification of TGGAA (pentanucleotide repeat), GGCCTG (hexanucleotide repeat), and ATTTT (pentanucleotide repeat), respectively. Currently, no FDA-approved treatments can address the underlying causes of SCAs. The primary approach to managing these conditions is symptomatic, aimed at alleviating specific symptoms such as seizures, tremors, depression, ataxia, and eye-related issues. This may involve using antiepileptic drugs for seizures, botulinum toxin injections for dystonia, beta-blockers, primidone for tremors, antidepressants for depression, and levodopa for parkinsonism, among other interventions.

·       SCA accounts for 3% to 5% of the ataxic diagnosed population, with an estimated prevalence of 1 to 5 cases in 100,000 people.

 

Thelansis’s “Spinocerebellar Ataxia (SCA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Spinocerebellar Ataxia (SCA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Spinocerebellar Ataxia (SCA) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Spinocerebellar Ataxia (SCA) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Spinocerebellar Ataxia (SCA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Spinocerebellar Ataxia (SCA), Spinocerebellar Ataxia (SCA) market outlook, Spinocerebellar Ataxia (SCA) competitive landscape, Spinocerebellar Ataxia (SCA) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more